Jeffrey R. Stewart - 31 Mar 2025 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, CHIEF COMMERCIAL OFFICER
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Jeffrey R. Stewart
Issuer symbol
ABBV
Transactions as of
31 Mar 2025
Net transactions value
-$12,359,504
Form type
4
Filing time
02 Apr 2025, 17:00:09 UTC
Previous filing
04 Mar 2025
Next filing
20 Feb 2026
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Options Exercise $2,030,814 +25,700 +30% $79.02 112,066 31 Mar 2025 Direct
transaction ABBV Common Stock, $0.01 par value Sale $5,383,893 -25,700 -23% $209.49 86,366 31 Mar 2025 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale $6,975,611 -33,132 -38% $210.54 53,234 31 Mar 2025 Direct F2
holding ABBV Common Stock, $0.01 par value 1,338 31 Mar 2025 By spouse in trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to Buy) Options Exercise $2,030,814 -25,700 -100% $79.02 0 31 Mar 2025 Common Stock 25,700 $79.02 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.43 to $209.60, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.54 to $210.63, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reporting person disclaims beneficial ownership of all securities held by his spouse.
F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.